The short version of somatotroph fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-12 and is reviewed periodically as new material appears.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
| Property | Value | Notes |
|---|---|---|
| Primary marker | Insulin-like growth factor 1 | Slow-changing integrated indicator of axis activity |
| Secondary marker | Growth hormone | Pulsatile; requires repeated or timed sampling |
| Typical analytical method | Immunoassay | Antibody-based quantification in serum |
| Common sample matrix | Serum | Collected under standardized conditions |
| Key interpretation factor | Age-stratified reference ranges | Baseline marker concentrations shift with age |
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
The 'Fortuna' GM potato variety developed by BASF was made resistant to late blight by introgressing two resistance genes, blb1 and blb2, from S. bulbocastanum, a wild potato native to Mexico. Rpi-blb1 is a nucleotide-binding leucine-rich repeat (NB-LRR/NLR), an R-gene-produced immunoreceptor. In October 2011, BASF requested cultivation and marketing approval as a feed and food from the EFSA. In 2012, GMO development in Europe was stopped by BASF. In November 2014, the United States Department of Agriculture (USDA) approved a genetically modified potato developed by Simplot, which contains genetic modifications that prevent bruising and produce less acrylamide when fried than conventional potatoes; the modifications do not cause new proteins to be made, but rather prevent proteins from being made via RNA interference. Genetically modified varieties have met public resistance in the U.S. and in the European Union.
=== Homemade water filters === Water filters can be made on-site using local materials such as sand and charcoal (e.g. from firewood burned in a special way). These filters are sometimes used by soldiers and outdoor enthusiasts. Due to their low cost they can be made and used by anyone. The reliability of such systems is highly variable. Such filters can do little, if anything, to mitigate germs and other harmful constituents and can give a false sense of security that the water so produced is potable. Water processed through an improvised filter should undergo secondary processing such as boiling to render it safe for consumption.
Kalra graduated from Christian Medical College, Ludhiana. He completed his postgraduation (MD) in Medicine at Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, and his fellowship (DM) in Endocrinology and Metabolism at the All India Institute of Medical Sciences, New Delhi.
By conceptualizing tissue-biofluid as information channels, significant biofluid proxies can be identified and then used for the guided development of clinical diagnostics. Candidate biomarkers are then predicted based on information transfer criteria across the tissue-biofluid channels. Significant biofluid-tissue relationships can be used to prioritize clinical validation of biomarkers.
Sources: en.wikipedia.org
=== Pivot to scientific instruments === HVEC had originally built products for clients in cancer therapy and industrial radiography, but its machines proved valuable for basic research. The company's proximity to MIT research gave it unique advantages in understanding accelerator requirements. Van de Graaff, Trump, and fellow board member William Buechner regularly consulted with physicists pushing the boundaries of nuclear structure studies, translating experimental needs into engineering specifications. In 1949, Brookhaven National Laboratory commissioned HVEC to build a 4 MeV Van de Graaff particle injector for its planned high-energy Cosmotron accelerator. When completed in 1953, the Cosmotron became the first accelerator to exceed billion-electronvolt potentials. HVEC's standard 2 MV accelerators also found nuclear science customers, including the Naval Research Laboratory and European universities. In 1951, HVEC adopted a Trump-designed MIT accelerator as a research accelerator prototype. This single-stage "CN" model was the first mass-produced research accelerator. CN machines operated at voltages up to 6.5 megavolts and established HVEC's reputation for reliability in nuclear research applications. In 1954, Canada's Chalk River Laboratories asked HVEC to modify the CN into higher-voltage tandem accelerator, yielding a highly profitable product line that sustained the company for fifteen years.
Cape Town ⟷ Kimberley ⟷ Johannesburg: General freight Durban ⟷ Richards Bay: Coastal freight Johannesburg ⟷ Durban: General freight (SA's busiest intermodal freight corridor) Johannesburg ⟷ Gqeberha / Ngqura: Automotive exports and manufactured goods Johannesburg ⟷ Polokwane: Mining supplies, and agricultural and manufacturing freight Johannesburg ⟷ Richards Bay: General freight Johannesburg ⟷ KuGompo City: Automotive and general freight Johannesburg ⟷ Komatipoort: Cross-border freight to Mozambique and the rest of the SADC Johannesburg ⟷ Beitbridge: Cross-border freight into Zimbabwe Johannesburg ⟷ Mahikeng / Ramatlabama: Cross-border freight into Botswana As of 2026, Transnet Freight Rail moves 17% of South Africa's freight annually, including 100% of its export coal and iron ore. The company coordinates its rail freight services with other Transnet divisions, such as ports, pipelines, and engineering. With over 25,000 employees, Transnet Freight Rail generates over R14 billion in annual revenue. For its 2025/2026 financial year, Transnet expected to transport a total rail cargo volume of around 168 million tons, up around 5%, from 160.1 million tons the year before. Under the South African Government's rail restructuring plan, the goal is for Transnet to reach a transport capacity of 185 million tons, with a further 65 million tons transported by private operators, by 2030. This would make for a total South African cargo rail capacity of 250 million tons per year.
Aging dogs require specialized catering. Commercially available senior dog diets address their physiological changes through various ingredients and nutrients. When looking for a senior dog food, one of the first things that should be taken into consideration is the energy content of the diet. The maintenance energy requirements decrease as a dog ages due to the loss in lean body mass that occurs. Therefore, senior dogs will require a diet with a lowered energy content compared to non senior diets. Although senior dogs require lower energy content diets, they will also require diets that are higher in protein and protein digestibility. This is due to the fact that dogs have a reduced ability to synthesize proteins as they age. Joint and bone health is an important factor to be considered when purchasing a senior dog food. The addition of glucosamine and chondroitin sulfate has been shown to improve cartilage formation, the composition of synovial fluid, as well as improve signs of osteoarthritis. The calcium to phosphorus ratio of senior dog foods is also important. Calcium and phosphorus are considered essential nutrients, according to AAFCO. Gastrointestinal health is another important factor to consider in the aging dog. Sources of fiber such as beet pulp and flaxseed should be included within senior dog foods to help improve stool quality and prevent constipation. A current technology that is being used to improve gastrointestinal health of aging dogs is the addition of fructooligosaccharides and mannanoligosaccharides.
Sources: en.wikipedia.org
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.
Assay calibration and antibody specificity differ between platforms, so identical samples can yield different numbers. A method change within one laboratory can shift results without any biological change. Cross-validation is often needed for multi-site work.
They capture only one moment in a pulsatile pattern and are strongly influenced by recent activity and meals. Repeated sampling or overnight profiles provide a more representative view. Provocative testing is an alternative when a dynamic response is of interest.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.